CN106172856A - A kind of functional fermented soybean milk and preparation method and application - Google Patents
A kind of functional fermented soybean milk and preparation method and application Download PDFInfo
- Publication number
- CN106172856A CN106172856A CN201610575321.3A CN201610575321A CN106172856A CN 106172856 A CN106172856 A CN 106172856A CN 201610575321 A CN201610575321 A CN 201610575321A CN 106172856 A CN106172856 A CN 106172856A
- Authority
- CN
- China
- Prior art keywords
- functional
- soyabean milk
- lactobacillus plantarum
- milk
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 71
- 239000008267 milk Substances 0.000 title claims abstract description 71
- 210000004080 milk Anatomy 0.000 title claims abstract description 71
- 244000068988 Glycine max Species 0.000 title claims abstract description 70
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims description 19
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 32
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 32
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 32
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940116269 uric acid Drugs 0.000 claims abstract description 14
- 238000000855 fermentation Methods 0.000 claims description 25
- 230000004151 fermentation Effects 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 12
- 230000036772 blood pressure Effects 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 241000186660 Lactobacillus Species 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 229940039696 lactobacillus Drugs 0.000 abstract description 4
- 235000020124 milk-based beverage Nutrition 0.000 abstract description 3
- 235000013406 prebiotics Nutrition 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 230000002335 preservative effect Effects 0.000 abstract description 3
- 230000004531 blood pressure lowering effect Effects 0.000 abstract description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 22
- 102100033220 Xanthine oxidase Human genes 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- 230000001629 suppression Effects 0.000 description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000031700 light absorption Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/005—Cheese substitutes mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/02—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
- A23C20/025—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of functional soyabean milk, ferments through Lactobacillus plantarum, and described Lactobacillus plantarum is Lactobacillus plantarum X7021, and the preserving number of described Lactobacillus plantarum X7021 is: CCTCC NO:M2015039.The functional soyabean milk of the present invention has good uric acid resisting, blood pressure lowering effect and good curdled milk effect;Not only have common soyabean milk drinks function, also has the prebiotic health care of lactobacillus, simultaneously without any preservative, and has more preferable mouthfeel, has broad application prospects.
Description
Technical field
The invention belongs to functional food technical field, specifically, be about a kind of functional fermented soybean milk and system thereof
Preparation Method and application.
Background technology
Along with raising and the living-pattern preservation of living standards of the people, hypertension, the prevalence of hyperuricemia significantly increase
Add.In addition to using traditional medical treatment regime, it is also possible to preferably prevent by healthy dietary habit and reduce generation
The incidence rate of thanking property disease.Therefore, increasing people starts edible health food such as: Organic food, functional food etc..Merit
Energy property food refers to the food with specific function, is suitable for specific crowd and eats, and the function of scalable body, the most not with treatment
For the purpose of and human body do not produced any acute, the subacute or food of chronic hazard.
Soyabean milk is welcome by consumers in general deeply because its protein content is high and has abundant nutritional labeling, usually through
Lactic acid bacteria fermentation is prepared as functional soyabean milk, and the functional soyabean milk using different lactic acid bacteria fermentations to obtain has different mouths
Sense, nutritional labeling and function.Substantial amounts of researcher has filtered out various plants lactobacillus, and has prepared several functions bean
Breast, such as: Chinese patent CN104694409A discloses a kind of Lactobacillus plantarum, preservation entitled Lactobacillus plantarum Y-9, and preservation is compiled
Number be CCTCC NO:M2013391, and disclose this Lactobacillus plantarum in preparing medicine or food for reduce cholesterol,
Blood pressure lowering, raising immunity, fat-reducing or the purposes of regulating intestinal canal flora.CN1927005A disclose one have increase bone close
Degree, the fermentation soybean milk and preparation method thereof of Angiotensin-converting enzyme inhibition function, wherein use lactobacillus helveticus TUST005
The composite ferment being main with diacetyl streptococcus ferments, and the fermentation soybean milk tool of preparation has efficacy in lowering high blood pressure.
Prior art does not the most find the fermented soybean milk with xanthine oxidase (XO) suppression function.XO is that human body is fast
Purine metabolism generates the key enzyme of uric acid, when XO is suppressed, is effectively reduced the formation of internal uric acid.Soyabean milk is a kind of purine content
Higher food, has patient's general recommendations fasting of hyperuricemia and gout.If soyabean milk is after lactic acid bacteria fermentation, produce
The rejection ability of XO, can effectively reduce soyabean milk eater and the risk of hyperuricemia occurs.Additionally, two or more metabolism
Syndrome (hyperlipemia, hypertension, hyperglycemia and hyperuricemia are commonly called as " four is high ") simultaneous situation is in obese people
Much.Therefore, research and develop a kind of functional fermented soybean milk with higher XO suppression ratio, there is blood pressure reduction effect simultaneously, and
Good mouthfeel just tool is kept to be of great significance.
Summary of the invention
First purpose of the present invention is to provide a kind of functional soyabean milk, has higher XO and angiotensin-converter
Enzyme (ACE) suppression ratio, and keep good mouthfeel.
Second object of the present invention is to provide the preparation method of described functional soyabean milk.
For achieving the above object, the present invention adopts the following technical scheme that
A kind of functional soyabean milk, obtains through Lactobacillus plantarum fermentation, and described Lactobacillus plantarum is Lactobacillus plantarum
X7021, its preserving number is: CCTCC NO:M2015039.
The preparation method of described functional soyabean milk, comprises the technical steps that:
1) Lactobacillus plantarum X7021 lyophilizing mycopowder is taken out defrosting, be seeded to the MRS training of sterilizing by the volume ratio of 2-6%
Support in base, be placed in 37 DEG C, cultivate under the conditions of 200rpm and take out to during exponential phase, obtain activating bacterium solution;
2) by step 1) activation bacterium solution be seeded in the soyabean milk of sterilizing according to the volume ratio of 2-6%, in 33-42 DEG C of standing
Fermentation 6-12h, after-ripening 2-48h under the conditions of 0-10 DEG C, obtain functional soyabean milk.
Preferably, described step 2) in volume ratio be 5%.
Preferably, described step 2) in fermentation temperature be 40 DEG C.
Preferably, described step 2) in fermentation time be 9h.
Third object of the present invention is to provide the application in reducing uric acid of described functional soyabean milk.
Fourth object of the present invention is to provide the application in blood pressure lowering of described functional soyabean milk.
Compared with prior art, there is advantages that
1) the functional soyabean milk of the present invention has good uric acid resisting and blood pressure lowering effect.
2) the Lactobacillus plantarum acid producing ability that the functional soyabean milk of the present invention uses is strong, the curdled milk of the functional soyabean milk of preparation
Respond well.
3) what the functional soyabean milk of the present invention not only had a common soyabean milk drinks function, also has the prebiotic health care of lactobacillus
Function, and without any preservative, meet the trend of beverage industry " green, nature, health ", there is wide application
Prospect.
Preservation explanation
Lactobacillus plantarum X7021 (the Lactobacillus plantarum X7021) bacterial strain of the present invention, has another name called plant breast
Bacillus S1L12 (Lactobacillus plantarum S1L12), is saved in Chinese Typical Representative on January 16th, 2015 and cultivates
Thing preservation center (China Center for Type Culture Collection is called for short CCTCC), depositary institution address:
China. Wuhan. Wuhan University, deposit number is CCTCC NO:M2015039.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention will be further described.Should be understood that following example are merely to illustrate this
Invent not for limiting the scope of the present invention.
In the present invention, the Lactobacillus plantarum X7021 of application derives from bean curd with odor saltwater brine.
MRS culture medium prescription: 10.0g peptone, 5.0g beef powder, 4.0g yeast powder, 20.0g glucose, 1.0mL tween
80,2.0g dipotassium hydrogen phosphate, 5.0g sodium acetate, 2.0g Triammonium citrate, 0.2g magnesium sulfate, 0.05g manganese sulfate, 15.0g agar
Powder and 1000mL distilled water.
Other raw materials of the present invention and equipment are commercially available.
Product skyr standard: the pH value of functional soyabean milk when measuring fermentation termination, it is the most that pH value the lowest explanation system produces acid,
The curdled milk effect of functional soyabean milk is the best.
Embodiment 1: the preparation of Lactobacillus plantarum lyophilizing mycopowder
1) in aseptic operating platform, a small amount of bacterium solution of picking from the glycerol pipe of Lactobacillus plantarum X7021, put down at MRS solid
Lining out, cultivates 36-48h in 37 DEG C, and from MRS solid plate, picking list colony inoculation is in MRS culture medium, detests in 37 DEG C
Oxygen cultivates 18h, is then inoculated in the fermentation tank containing MRS culture medium, anaerobic fermentation 24h, is then centrifuged 10 under the conditions of 6000rpm
Minute, collect thalline, and wash 2 times with the sterile phosphate buffer that pH value is 6.4, recentrifuge, obtain bacterium mud.
2) by step 1) the bacterium mud prepared is sufficiently mixed emulsifying with sterilized freeze drying protectant by weight 1:2, obtains
Emulsion mixture.
3) by step 2) emulsion mixture pre-freeze more than 4h below 45 DEG C of preparing, place into lyophilizing in freeze dryer,
To Lactobacillus plantarum X7021 lyophilizing mycopowder.
4) after measured, step 3) viable count in the Lactobacillus plantarum lyophilizing mycopowder prepared is 1.0 × 1010-1.5×
1011CFU/g。
Wherein, above-mentioned steps 2) in freeze drying protectant contain 20% defatted milk powder, 6% trehalose, 2.5% glutamic acid
Sodium, 2% glycerol and 0.5% cysteine hydrochloride (being mass percent above).
Embodiment 2: the preparation of soyabean milk raw material
Soyabean milk is made in Non-transgenic soybean making beating, boiling sterilization 30 minutes in 100 DEG C of boiling water baths, it is prepared as sterilizing bean
Breast, standby.
The preparation process of soyabean milk is as follows: selected Non-transgenic soybean → cleaning → according to bean: water=1:3 (volume ratio) adds steaming
The hot water of 85 DEG C of distilled water soaked overnight → addition certain volume carries out defibrator process → filtered through gauze → boil 30min → cooling.
Embodiment 3-5: Lactobacillus plantarum is used for preparing functional fermented soybean milk
The preparation method of functional soyabean milk is as follows:
1) Lactobacillus plantarum X7021 lyophilizing mycopowder embodiment 1 prepared takes out and thaws, and is seeded to by the volume ratio of 2%
In the MRS culture medium of sterilizing, it is placed in 37 DEG C, cultivates under the conditions of 200rpm and take out to when entering exponential phase, obtain activating bacterium
Liquid.
2) by step 1) activation bacterium solution according to the volume ratio of 2-6% be seeded to embodiment 2 preparation sterilizing soyabean milk in,
Standing for fermentation 6-12h in 33-42 DEG C of constant incubator, after-ripening 2-48h under the conditions of 0-10 DEG C, obtain functional soyabean milk.
3) pH value of functional soyabean milk during detection fermentation termination.
It is observed that the functional soyabean milk curdled milk of preparation is in order.
The concrete fermentation condition of embodiment 3-5 is as shown in table 1:
PH value after the fermentation condition of table 1 embodiment 3-11 and fermentation
Embodiment 6: functional soyabean milk uric acid resisting ability detects
Xanthine oxidase (XO) is can be catalyzed hypoxanthine in human body to be oxidized to xanthine, and xanthine oxidase turns to uric acid
Key enzyme, being therefore that treatment is gentle solves gout or the drug target of hyperuricemia disease.The activity of suppression XO can reduce gout
Or the uric acid content that hyperuricemia disease is in the patient, thus slow down gout symptom.The present embodiment is fermented bean by detection functionality
The external XO suppression ratio of breast measures the uric acid resisting vigor of the functional soyabean milk of the present invention.The concrete assay method of XO suppression ratio is such as
Under:
The hydrochloric acid adjustment pH value of functional soyabean milk 2mol/L embodiment 3-5 prepared, to 4.0, is subsequently placed in centrifugal
Guan Zhong, 8000rpm are centrifuged 10 minutes, obtain supernatant, take part supernatant and with 2mol/L NaOH adjustment pH value to 7.5, then
Secondary 8000rpm is centrifuged 10 minutes, and the supernatant obtained is as testing sample.
Test group 1: draw testing sample 25 μ L, the xanthine solution adding 0.5mmol/L (is dissolved in 20m mol/L
In the sodium phosphate buffer of pH7.5) 25 μ L, and temperature bath 5 minutes under the conditions of 25 DEG C, being subsequently added concentration is the molten of 100mU/mL
Solution xanthine oxidase 50 μ L in same sodium phosphate buffer, starts reaction, reacts 30 minutes under the conditions of 25 DEG C,
Rear addition 25 μ L concentration is that the HCl of 1mol/L terminates reaction, the light absorption value A of product uric acid under the conditions of mensuration 290nm1。
Test group 2: draw testing sample 25 μ L, adds 25 μ L xanthine solution, and in 25 DEG C of temperature bath 5min, is subsequently added
The 50 above-mentioned sodium phosphate buffers of μ L, react 30 minutes under the conditions of 25 DEG C, are eventually adding the HCl that 25 μ L concentration are 1mol/L and terminate
Reaction, measures the light absorption value A under the conditions of 290nm2。
Matched group 1: draw above-mentioned sodium phosphate buffer 25 μ L, adds 25 μ L xanthine solution, and in 25 DEG C of temperature baths 5 points
Clock, is subsequently added xanthine oxidase (XO) 50 μ L and starts reaction, react 30 minutes, be eventually adding 25 μ L dense under the conditions of 25 DEG C
The HCl that degree is 1mol/L terminates reaction, the light absorption value A of product uric acid under the conditions of mensuration 290nm3。
Matched group 2: draw 25 μ L xanthine solution, and in 37 DEG C of temperature baths 5 minutes, be subsequently added the 75 above-mentioned sodium phosphates of μ L and delay
Rush liquid, react 30 minutes under the conditions of 37 DEG C, be eventually adding the HCl that 25 μ L concentration are 1mol/L and terminate reaction, measure 290nm bar
Light absorption value A under part4。
Calculated the suppression ratio of XO by the change of light absorption value, computing formula is as follows:
XO suppression ratio (%)=[(A1-A2)-(A3-A4)]/(A3-A4) × 100%
Wherein: A1、A2、A3And A4Product under the conditions of expression test group 1, test group 2, matched group 1 and matched group 2 respectively
Light absorption value.
Each testing sample is made three Duplicate Samples respectively, and the meansigma methods of the XO suppression ratio taking each Duplicate Samples is sample
XO suppression ratio, result is as shown in table 2.
As can be seen from Table 2, without the soyabean milk of Lactobacillus plantarum fermentation without XO inhibitory activity, and through Lactobacillus plantarum
The soyabean milk of X7021 fermentation has stronger XO inhibitory activity, illustrates that the functional soyabean milk of the present invention has good uric acid resisting merit
Effect;Compared with the soyabean milk fermented without Lactobacillus plantarum.
Embodiment 7: functional soyabean milk blood pressure lowering ability detects
Angiotensin converting enzyme (ACE) is a kind of dipeptides carboxylic acid played an important role during human blood-pressure regulates, main
The regulation of renin angiotensin aldosterone system to be participated in.ACE catalyzing hydrolysis angiotensin is transformed into and has strong boosting
The Angiotensin II of effect, resolves into inactive fragments by the bradykinin playing vasorelaxation action simultaneously, causes elevation of the blood pressure.
The activity of suppression ACE can reduce the generation of Angiotensin II and the inactivation of bradykinin, thus reduces the mesh of blood pressure
's.The present embodiment measures the blood pressure lowering energy of Lactobacillus plantarum X7021 Fermentation Function soyabean milk by the outer ACE suppression ratio of detection bodies
Power.The concrete detection method of ACE suppression ratio is as follows:
The hydrochloric acid adjustment pH value of functional soyabean milk 2mol/L embodiment 3-5 prepared, to 4.0, is subsequently placed in centrifuge tube
In, 8000rpm is centrifuged 10min, obtains supernatant, then the NaOH of the pH value 2mol/L of part supernatant is adjusted pH value extremely
8.3,8000rpm is centrifuged 10min again, obtains supernatant, be stored in-20 DEG C stand-by as testing sample.
Test group: add testing sample 25 μ L in 1.5mLEP pipe, add the ACE that concentration is 310mU/mL and (be dissolved in
0.1mol/L NaCl Han 0.5mol/L, pH value is in the sodium borate buffer solution of 8.3) 10 μ L, and temperature bath 5min at 37 DEG C,
(HHL is dissolved in 0.1mol/L containing 0.5mol/L to be subsequently adding the hippuroyl histidyl leucine that 50 μ L concentration are 5.0m mol/L
NaCl, pH value is in the sodium borate buffer solution of 8.3) starting reaction, isothermal reaction 1h at 37 DEG C, then 100 DEG C of conditions
Lower heating in water bath 10min makes enzyme inactivation terminate reaction.
Matched group: the testing sample in test group is replaced with the above-mentioned sodium borate buffer liquid of same volume.
Use after high-efficient liquid phase chromatogram technique analysis reaction the content of hippuric acid in test group and matched group system, with high-efficient liquid
The content of the peak area A correspondence hippuric acid in phase chromatograph collection of illustrative plates, and according to below equation calculating ACE suppression ratio:
ACE suppression ratio (%)=(AComparison-ATest)/AComparison× 100%
In formula: AComparisonPeak area for matched group;ATestPeak area for test group.
The condition determination of high performance liquid chromatography is: chromatographic column: WondaSil C18 chromatographic column (250 × 4.6mm, 5 μm);Stream
Dynamic phase: A be ultra-pure water (containing 0.1%TFA), B be acetonitrile;Elution requirement: 0min, 20%B;10min, 100%B;16min,
20%B;20min, 20%B;Flow velocity: 0.8mL/min;Column temperature: 30 DEG C;Detection wavelength: 228nm;Sample size: 10 μ L.
Result of the test is as shown in table 2.
Functional soyabean milk effect prepared by table 2 embodiment 3-5 compares
As can be seen from Table 2, soyabean milk is after Lactobacillus plantarum X7021 ferments, and ACE suppression ratio all raises, and the present invention is described
Functional fermented soybean milk there is obvious blood pressure reduction effect.
Embodiment 8, functional soyabean milk mouthfeel are tested
Randomly choose 30 citizen and foretaste the functional soyabean milk (test prepared according to the preparation method of the present invention simultaneously
Group), commercially available common soyabean milk (contrast groups 1) and commercially available usual functionality soyabean milk (contrast groups 2), add up its satisfaction, such as table 3
Shown in:
Table 3
By the result of table 3 it can be seen that the functional satisfaction than commercially available soyabean milk and functional soyabean milk of the present invention all
Height, the functional soyabean milk of the present invention has good mouthfeel.
In sum, the functional soyabean milk that the present invention uses Lactobacillus plantarum fermentation to prepare has obvious uric acid resisting
And blood pressure, it is suitable for metabolic arthritis and edible for patients with elevated blood pressure;The Lactobacillus plantarum acid producing ability used is strong, and curdled milk is respond well;No
Only have common soyabean milk drinks function, also has the prebiotic health care of lactobacillus, simultaneously without any preservative, and tool
There is more preferable mouthfeel, therefore there is prospects for commercial application widely.
Being described in detail the specific embodiment of the present invention above, but it is only used as example, the present invention is not limiting as
In particular embodiments described above.To those skilled in the art, any equivalent modifications that this invention is carried out and replacing
In generation, is the most all among scope of the invention.Therefore, the equalization made without departing from the spirit and scope of the invention converts and repaiies
Change, all should contain within the scope of the invention.
Claims (7)
1. a functional soyabean milk, obtains through Lactobacillus plantarum fermentation, it is characterised in that described Lactobacillus plantarum is plant breast
Bacillus X7021, its preserving number is: CCTCC NO:M2015039.
The preparation method of functional soyabean milk the most as claimed in claim 1, comprises the technical steps that:
1) Lactobacillus plantarum X7021 lyophilizing mycopowder is taken out defrosting, be seeded to the MRS culture medium of sterilizing by the volume ratio of 2-6%
In, it is placed in 37 DEG C, cultivates under the conditions of 200rpm and take out to during exponential phase, obtain activating bacterium solution;
2) by step 1) activation bacterium solution be seeded in sterilizing soyabean milk according to the volume ratio of 2-6%, in 33-42 DEG C of standing for fermentation 6-
After-ripening 2-48 hour under the conditions of 12h, 0-10 DEG C, obtains functional soyabean milk.
3. preparation method as claimed in claim 2, it is characterised in that described step 2) in volume ratio be 5%.
4. preparation method as claimed in claim 2, it is characterised in that described step 2) in fermentation temperature be 40 DEG C.
5. preparation method as claimed in claim 2, it is characterised in that described step 2) in fermentation time be 9h.
The functional soyabean milk the most as claimed in claim 1 application in reducing uric acid.
The functional soyabean milk the most as claimed in claim 1 application in blood pressure lowering.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610575321.3A CN106172856B (en) | 2016-07-21 | 2016-07-21 | Functional fermented soybean milk and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610575321.3A CN106172856B (en) | 2016-07-21 | 2016-07-21 | Functional fermented soybean milk and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106172856A true CN106172856A (en) | 2016-12-07 |
CN106172856B CN106172856B (en) | 2020-07-17 |
Family
ID=57491100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610575321.3A Active CN106172856B (en) | 2016-07-21 | 2016-07-21 | Functional fermented soybean milk and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106172856B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109504636A (en) * | 2018-12-27 | 2019-03-22 | 内蒙古农业大学 | A kind of lactobacillus plantarum P12 and application thereof |
CN109517767A (en) * | 2019-01-21 | 2019-03-26 | 北京农学院 | A kind of lactobacillus plantarum strain, soymilk and its production method based on strain fermentation production |
CN110638037A (en) * | 2019-08-14 | 2020-01-03 | 浙江黑金生物科技有限公司 | Application of lactobacillus plantarum X7022, black garlic enzyme and preparation method and application of black garlic enzyme |
CN111635870A (en) * | 2020-05-26 | 2020-09-08 | 华东理工大学 | Leavening agent, direct-feeding fermentation method of stinky tofu marinating liquid and stinky tofu marinating liquid |
CN114376152A (en) * | 2022-01-12 | 2022-04-22 | 东北农业大学 | Preparation method of fermented soybean milk and application of fermented soybean milk in enhancing immunocompetence |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102747009A (en) * | 2012-04-18 | 2012-10-24 | 北京和美科盛生物技术有限公司 | Lactobacillus plantarum PY-1 and use method of lactobacillus plantarum PY 1 in fermentation of dairy products |
CN104694409A (en) * | 2013-12-06 | 2015-06-10 | 深圳华大基因科技有限公司 | Lactobacillus plantarum and uses thereof |
CN104719492A (en) * | 2015-03-27 | 2015-06-24 | 柳陈坚 | Preparation method for active probiotic fermentation sour soybean milk |
CN104824171A (en) * | 2015-04-21 | 2015-08-12 | 厦门医学高等专科学校 | Bean-fermented drink and preparation method thereof |
CN105638912A (en) * | 2016-01-07 | 2016-06-08 | 苏州金记食品有限公司 | Preparation method of solidified sour soybean milk |
CN105661230A (en) * | 2016-01-20 | 2016-06-15 | 天津科技大学 | Probiotic functional beverage and probiotic food prepared from Lens culinaris by fermentation |
-
2016
- 2016-07-21 CN CN201610575321.3A patent/CN106172856B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102747009A (en) * | 2012-04-18 | 2012-10-24 | 北京和美科盛生物技术有限公司 | Lactobacillus plantarum PY-1 and use method of lactobacillus plantarum PY 1 in fermentation of dairy products |
CN104694409A (en) * | 2013-12-06 | 2015-06-10 | 深圳华大基因科技有限公司 | Lactobacillus plantarum and uses thereof |
CN104719492A (en) * | 2015-03-27 | 2015-06-24 | 柳陈坚 | Preparation method for active probiotic fermentation sour soybean milk |
CN104824171A (en) * | 2015-04-21 | 2015-08-12 | 厦门医学高等专科学校 | Bean-fermented drink and preparation method thereof |
CN105638912A (en) * | 2016-01-07 | 2016-06-08 | 苏州金记食品有限公司 | Preparation method of solidified sour soybean milk |
CN105661230A (en) * | 2016-01-20 | 2016-06-15 | 天津科技大学 | Probiotic functional beverage and probiotic food prepared from Lens culinaris by fermentation |
Non-Patent Citations (5)
Title |
---|
丁翘等: "植物乳杆菌NCU116对高脂饮食大鼠肾脏的保护作用", 《食品科学》 * |
孙贵朋: "臭豆腐卤液中微生物多样性研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
张京等: "一株乳酸菌的鉴定及其在酸豆乳加工中的应用", 《中国酿造》 * |
杨殿斌等: "降血尿酸乳酸菌筛选及其对高尿酸血症模型大鼠作用研究", 《中国微生态学杂志》 * |
马千里等: "植物乳杆菌的益生特性及其在乳制品中的应用", 《中国奶牛》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109504636A (en) * | 2018-12-27 | 2019-03-22 | 内蒙古农业大学 | A kind of lactobacillus plantarum P12 and application thereof |
CN109517767A (en) * | 2019-01-21 | 2019-03-26 | 北京农学院 | A kind of lactobacillus plantarum strain, soymilk and its production method based on strain fermentation production |
CN109517767B (en) * | 2019-01-21 | 2020-07-10 | 北京农学院 | Lactobacillus plantarum strain, soymilk produced based on fermentation of strain and production method of soymilk |
CN110638037A (en) * | 2019-08-14 | 2020-01-03 | 浙江黑金生物科技有限公司 | Application of lactobacillus plantarum X7022, black garlic enzyme and preparation method and application of black garlic enzyme |
CN111635870A (en) * | 2020-05-26 | 2020-09-08 | 华东理工大学 | Leavening agent, direct-feeding fermentation method of stinky tofu marinating liquid and stinky tofu marinating liquid |
CN111635870B (en) * | 2020-05-26 | 2022-07-01 | 华东理工大学 | Leavening agent, direct-feeding fermentation method of stinky tofu marinating liquid and stinky tofu marinating liquid |
CN114376152A (en) * | 2022-01-12 | 2022-04-22 | 东北农业大学 | Preparation method of fermented soybean milk and application of fermented soybean milk in enhancing immunocompetence |
Also Published As
Publication number | Publication date |
---|---|
CN106172856B (en) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106172856A (en) | A kind of functional fermented soybean milk and preparation method and application | |
CN104845912B (en) | One lactobacillus plantarum | |
CN107446852B (en) | One lactobacillus plantarum and its application in terms of fermented feed | |
CN107197966B (en) | Method for preparing GABA tea through microbial fermentation | |
CN111778192B (en) | Naqu 4580 probiotics with antihypertensive activity and preparation and application thereof | |
CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
CN101731511B (en) | Probiotic active product and preparation method thereof | |
CN101623099A (en) | Blueberry probiotic powder and process method thereof | |
CN106190908B (en) | A kind of application of lactobacillus plantarum X7021 | |
JP7158761B2 (en) | Starter cultures containing mixtures of lactic acid bacteria strains, fermented products produced using such starter cultures, and uses of the fermented products | |
CN100484963C (en) | Exo-polysaccharide of lactobacillus casei and crude product, prepartion method and application | |
CN106190893A (en) | One strain is applicable to the Lactobacillus fermenti of vinegar brewing and the preparation method and application of mycopowder thereof | |
CN113549567B (en) | Lactobacillus rhamnosus NSL0401 with defecation promoting function and application thereof | |
CN106937749A (en) | The method that bean dregs are modified with monascus | |
CN113604395A (en) | Lactobacillus plantarum capable of fermenting dendrobium and improving skin quality by fermentation liquor of dendrobium | |
TW201625282A (en) | Novel Acetobacter and Gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | |
CN106591202B (en) | A kind of feed process improving Miyarisan Fermentative growth efficiency | |
CN106434489A (en) | High-wine-yield Klebsiella pneumoniae and application thereof | |
CN104365858B (en) | A kind of preparation method of fermented type ginkgo peanut milk drink | |
CN113186069A (en) | Lactobacillus strain microbial fermentation process | |
CN106497982A (en) | A kind of α glucosidase inhibitors and preparation method thereof | |
CN104365845B (en) | A kind of preparation method of fermented type Mung Bean Milk Drink | |
CN108887680A (en) | A kind of efficient small molecule nutritional preparation and preparation method thereof for promoting intestinal beneficial bacterium proliferation | |
CN102246969A (en) | Starter and preparation method and use thereof | |
CN115786189A (en) | Direct vat set starter for high-yield antihypertensive peptide and application of direct vat set starter in preparation of antihypertensive yogurt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |